Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common stock, par value $0.0001 per share
Symbol
ABOS on Nasdaq
Shares outstanding
60,660,421
Price per share
$2.11
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
14,951,519
Total reported value
$31,544,833
% of total 13F portfolios
0%
Share change
-124,019
Value change
-$227,783
Number of holders
47
Price from insider filings
$2.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 25% $16,517,669 15,016,063 RA Capital Management, L.P. 27 Mar 2025
Sands Capital Alternatives, LLC 5.6% $3,861,295 3,417,075 Sands Capital Alternatives, LLC 30 Jun 2025
FRANKLIN RESOURCES INC 3.8% $3,941,714 2,305,096 Franklin Resources, Inc. 30 Sep 2025

As of 31 Dec 2025, 47 institutional investors reported holding 14,951,519 shares of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS). This represents 25% of the company’s total 60,660,421 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) together control 24% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Sands Capital Alternatives, LLC 5.6% 3,417,075 0% 1.4% $7,210,028
FRANKLIN RESOURCES INC 3.8% 2,305,096 0% 0% $4,863,753
VANGUARD GROUP INC 2.7% 1,653,772 +0.14% 0% $3,489,459
Knollwood Investment Advisory, LLC 2.7% 1,628,510 0% 0.32% $3,436,156
Alyeska Investment Group, L.P. 1.5% 939,603 0% 0.01% $1,982,562
Laurion Capital Management LP 1.4% 867,046 0% 0.12% $1,829,467
Pathstone Holdings, LLC 1.4% 859,110 0% 0.01% $1,812,722
Hudson Bay Capital Management LP 1.2% 725,000 -0% 0.01% $1,529,750
RENAISSANCE TECHNOLOGIES LLC 0.7% 423,100 -28% 0% $892,741
GEODE CAPITAL MANAGEMENT, LLC 0.68% 410,206 +2.9% 0% $865,686
SG Americas Securities, LLC 0.66% 401,047 -0.7% 0% $846,000
BlackRock, Inc. 0.28% 169,505 -3% 0% $357,655
MORGAN STANLEY 0.28% 166,905 +12% 0% $352,169
ACADIAN ASSET MANAGEMENT LLC 0.25% 152,780 +96% 0% $320,000
JANE STREET GROUP, LLC 0.23% 142,123 -31% 0% $299,879
GOLDMAN SACHS GROUP INC 0.19% 117,851 -20% 0% $248,666
STATE STREET CORP 0.17% 100,178 -6.1% 0% $211,376
CATALYST FINANCIAL PARTNERS LLC 0.15% 89,699 0% 0.02% $189,265
Prospera Financial Services Inc 0.08% 50,000 0% $105,500
DIMENSIONAL FUND ADVISORS LP 0.08% 49,062 +13% 0% $103,520
Intrepid Financial Planning Group LLC 0.05% 30,150 0% 0.02% $63,617
BARCLAYS PLC 0.05% 29,991 0% 0% $63,281
Catalyst Funds Management Pty Ltd 0.05% 29,600 0% 0.01% $62,456
OMERS ADMINISTRATION Corp 0.04% 22,454 0% $47,378
UBS Group AG 0.04% 21,562 -30% 0% $45,496

Institutional Holders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 14,951,519 $31,544,833 -$227,783 $2.11 47
2025 Q3 35,732,361 $61,097,340 -$2,856,744 $1.71 68
2025 Q2 37,585,884 $43,599,129 -$2,103,479 $1.16 69
2025 Q1 39,403,584 $43,344,870 -$3,628,850 $1.10 79
2024 Q4 42,499,401 $73,099,738 -$2,305,406 $1.72 78
2024 Q3 43,605,225 $107,681,203 -$212,803 $2.48 72
2024 Q2 43,581,156 $105,487,337 -$2,322,503 $2.42 81
2024 Q1 43,364,829 $175,565,762 +$20,042,386 $4.05 78
2023 Q4 38,441,008 $147,599,716 -$20,522,527 $3.84 67
2023 Q3 43,186,479 $179,213,677 +$71,103,757 $4.15 64
2023 Q2 26,328,948 $126,640,120 -$5,262,013 $4.81 52
2023 Q1 27,781,261 $112,787,020 -$4,579,764 $4.06 61
2022 Q4 28,727,743 $155,145,749 -$5,374,332 $5.40 59
2022 Q3 27,496,751 $275,793,298 +$19,526,193 $10.03 48
2022 Q2 25,628,401 $120,458,000 -$6,031,616 $4.70 44
2022 Q1 27,062,428 $105,815,702 -$3,031,020 $3.91 53
2021 Q4 25,569,796 $172,840,000 -$1,670,403 $6.76 50
2021 Q3 24,050,108 $357,352,000 +$306,574,000 $14.86 40